eflornithine has been researched along with P carinii Pneumonia in 23 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eflornithine was offered as compassionate treatment of 33 episodes of Pneumocystis carinii pneumonia in 31 patients with acquired immunodeficiency syndrome who were intolerant of and/or unresponsive to conventional trimethoprim-sulfamethoxazole or pentamidine therapy." | 7.68 | Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. ( Boylen, CT; Gilman, TM; Heseltine, PN; Paulson, YJ; Sharma, OP, 1992) |
| " In the present study, we have prospectively assessed the use of alpha-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, in the treatment of P carinii pneumonia in patients with AIDS who were intolerant or unresponsive to conventional drugs." | 7.67 | Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome. ( Golden, JA; Santi, DV; Sjoerdsma, A, 1984) |
| "Eflornithine is an antiprotozoal agent active against P." | 6.38 | Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. ( Berry, AJ; Sahai, J, 1989) |
| "The symposium provided dramatic evidence of the value of the use of polyamine inhibition via alpha-difluoromethylornithine (DFMO, eflornithine) for advances in chemotherapy of Trypanosoma brucei gambiense sleeping sickness and Pneumocystis carinii pneumonia in acquired immune deficiency syndrome (AIDS) and also for further understanding the metabolic importance of the ubiquitous polyamines in these organisms." | 5.06 | Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects. ( Bacchi, CJ; Barlow, JL; Bey, P; Clarkson, AB; McCann, PP; Schecter, PJ; Sjoerdsma, A; Walzer, PD, 1986) |
| "The combination of clindamycin plus primaquine appears to be the most effective alternative treatment for patients with P carinii pneumonia who are unresponsive to conventional antipneumocystis agents." | 4.81 | A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. ( Maloba, B; Nagar, S; Popara, M; Smego, RA, 2001) |
| "Eflornithine was offered as compassionate treatment of 33 episodes of Pneumocystis carinii pneumonia in 31 patients with acquired immunodeficiency syndrome who were intolerant of and/or unresponsive to conventional trimethoprim-sulfamethoxazole or pentamidine therapy." | 3.68 | Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. ( Boylen, CT; Gilman, TM; Heseltine, PN; Paulson, YJ; Sharma, OP, 1992) |
| " In the present study, we have prospectively assessed the use of alpha-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, in the treatment of P carinii pneumonia in patients with AIDS who were intolerant or unresponsive to conventional drugs." | 3.67 | Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome. ( Golden, JA; Santi, DV; Sjoerdsma, A, 1984) |
| "A 44-year-old man with acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) who suffered adverse effects from treatment with trimethoprim-sulfamethoxazole (TMP-SMX) and was then treated with pentamidine isethionate is described, and approved and investigational drugs used in the management of PCP in the AIDS patient are discussed." | 3.67 | Treatment of Pneumocystis carinii pneumonia in patients with AIDS. ( Hauptman, SP; Wordell, CJ, 1988) |
| "The diagnosis of Pneumocystis carinii pneumonia (PCP) rests on the isolation of this micro-organism in patients whose latest blood count, less than 2 months old, shows less than 250 CD4 lymphocytes per cubic mm and who present with signs of impaired lung function." | 2.38 | [Pneumocystis carinii pneumonia in HIV infection. Diagnosis, prognostic factors and curative treatment]. ( Girard, PM; Saimot, AG, 1991) |
| "Eflornithine is an antiprotozoal agent active against P." | 2.38 | Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. ( Berry, AJ; Sahai, J, 1989) |
| "She tested positive and suspected pneumocystosis (later confirmed) and began treatment with IV Septrin and hydrocortisone." | 1.28 | A maternal death caused by AIDS. Case report. ( Barton, SE; Gazzard, B; Kell, PD; Marwood, RP; Nelson, M; Smith, DE, 1991) |
| "Eflornithine appears to be a useful salvage therapy in patients failing first-line treatments." | 1.28 | Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. ( Davies, S; Gazzard, B; Gleeson, J; Nelson, M; Smith, D; Youle, M, 1990) |
| "Suramin and dapsone were weakly active." | 1.27 | Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. ( Clarkson, AB; Rosenberg, C; Williams, DE, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (47.83) | 18.7374 |
| 1990's | 11 (47.83) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Golden, JA | 2 |
| Sjoerdsma, A | 3 |
| Santi, DV | 2 |
| Schechter, PJ | 1 |
| Barlow, JL | 2 |
| Pastor, C | 1 |
| Lumbreras, C | 1 |
| Lizasoain, M | 1 |
| Chin, K | 1 |
| Merali, S | 1 |
| Sarić, M | 2 |
| Clarkson, AB | 4 |
| Ewig, S | 1 |
| Schäfer, H | 1 |
| Rockstroh, JK | 1 |
| Lüderitz, B | 1 |
| Fishman, JA | 1 |
| Smego, RA | 1 |
| Nagar, S | 1 |
| Maloba, B | 1 |
| Popara, M | 1 |
| Smith, DE | 2 |
| Davies, S | 2 |
| Smithson, J | 1 |
| Harding, I | 1 |
| Gazzard, BG | 1 |
| Sattler, FR | 1 |
| Feinberg, J | 1 |
| Saimot, AG | 1 |
| Girard, PM | 1 |
| Paulson, YJ | 1 |
| Gilman, TM | 1 |
| Heseltine, PN | 1 |
| Sharma, OP | 1 |
| Boylen, CT | 1 |
| Kell, PD | 1 |
| Barton, SE | 1 |
| Nelson, M | 2 |
| Marwood, RP | 1 |
| Gazzard, B | 2 |
| Smith, D | 1 |
| Youle, M | 1 |
| Gleeson, J | 1 |
| Grady, RW | 1 |
| Sahai, J | 1 |
| Berry, AJ | 1 |
| Tyms, AS | 2 |
| Barbarash, RA | 1 |
| Toll, L | 1 |
| Sahn, SA | 1 |
| McCann, PP | 1 |
| Bacchi, CJ | 1 |
| Bey, P | 1 |
| Schecter, PJ | 1 |
| Walzer, PD | 2 |
| Kim, CK | 1 |
| Foy, J | 1 |
| Linke, MJ | 1 |
| Cushion, MT | 1 |
| Wordell, CJ | 1 |
| Hauptman, SP | 1 |
| Williams, DE | 1 |
| Rosenberg, C | 1 |
| Catterall, JR | 1 |
| Potasman, I | 1 |
| Remington, JS | 1 |
5 reviews available for eflornithine and P carinii Pneumonia
| Article | Year |
|---|---|
[Current alternatives in the treatment of Pneumocystis carinii pneumonia in patients with AIDS].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Atovaquone; Clindamycin; Dapsone; Eflornit | 1994 |
Treatment of infection due to Pneumocystis carinii.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Atovaquone; Clindamycin; Dapsone; Eflornithine; Humans | 1998 |
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Child; Child, Preschool; Clindamycin | 2001 |
[Pneumocystis carinii pneumonia in HIV infection. Diagnosis, prognostic factors and curative treatment].
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Dapsone; Eflornithine; F | 1991 |
Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review.
Topics: Acquired Immunodeficiency Syndrome; Eflornithine; Humans; Opportunistic Infections; Pneumonia, Pneum | 1989 |
3 trials available for eflornithine and P carinii Pneumonia
| Article | Year |
|---|---|
Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; Chemotherapy, Adjuvant; Eflornithine | 1992 |
Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects.
Topics: Acquired Immunodeficiency Syndrome; Animals; Clinical Trials as Topic; Eflornithine; Humans; Pneumoc | 1986 |
Pneumocystis carinii pneumonia in the patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Bronchoscopy; Clinical Trials as Topic; Dapsone; Drug C | 1985 |
15 other studies available for eflornithine and P carinii Pneumonia
| Article | Year |
|---|---|
Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Eflornithine; Humans; Male; Middle Aged; Ornithine; Pneum | 1984 |
Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Child; Eflornithine; Female; Humans; Male; Mi | 1984 |
Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.
Topics: Administration, Oral; Animals; Eflornithine; Enzyme Inhibitors; Infusion Pumps, Implantable; Injecti | 1996 |
[Improved prognosis of first episode HIV associated Pneumocystis carinii pneumonia without preventive treatment: etiology and sequelae].
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Cause of Death; Eflornithine; Female | 1996 |
New developments in the treatment of Pneumocystis carinii pneumonia.
Topics: Adrenal Cortex Hormones; Aerosols; Dapsone; Drug Therapy, Combination; Eflornithine; Folic Acid Anta | 1992 |
Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Eflornithine; Female; Hearing Disorders; Humans; Male; Pn | 1992 |
A maternal death caused by AIDS. Case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; Eflornithine; Female; Humans; Isoniazid; Opportunistic In | 1991 |
Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy.
Topics: Acquired Immunodeficiency Syndrome; Eflornithine; Female; Homosexuality; Humans; Male; Pentamidine; | 1990 |
Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.
Topics: Animals; Deferoxamine; Disease Models, Animal; Eflornithine; Female; Pneumonia, Pneumocystis; Random | 1990 |
Difluoromethylornithine for Pneumocystis carinii?
Topics: Eflornithine; Humans; Ornithine; Pneumonia, Pneumocystis | 1985 |
Polyamine inhibitors.
Topics: Acquired Immunodeficiency Syndrome; Animals; Eflornithine; Humans; Ornithine; Pneumonia, Pneumocysti | 1986 |
Alpha-difluoromethylornithine infusion and cardiac arrest.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiprotozoal Agents; Eflornithine; Female; Heart Arrest; | 1986 |
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.
Topics: Amidines; Animals; Anti-Infective Agents; Carbanilides; Eflornithine; Male; Phenanthridines; Pneumon | 1988 |
Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Dapsone; | 1988 |
Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia.
Topics: Amphotericin B; Animals; Antiprotozoal Agents; Dapsone; Diminazene; Disease Models, Animal; Drug Com | 1988 |